Qiagen, DxS, Idaho Technology, Roche deal

Qiagen acquired DxS in a deal valued at $95 million in cash, plus up to $35 million if commercial and other milestones are met. Qiagen gains DxS' marketed portfolio of seven real-time PCR tests to predict patient response to cancer treatments. Qiagen said the assays are suitable for use with its existing platform instruments, including QIAsymphony and Rotor-Gene Q. Qiagen expects the acquisition to contribute $6 million in sales for the remainder of 2009 and $30 million in sales in 2010. Jefferies was an advisor for the deal. ...